Amphastar Pharmaceuticals logo
Amphastar Pharmaceuticals AMPH
$ 19.48 -0.46%

Annual report 2025
added 02-26-2026

report update icon

Amphastar Pharmaceuticals Income Statement 2011-2026 | AMPH

Annual Income Statement Amphastar Pharmaceuticals

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

1.25 B 1.31 B 2.25 B 1.76 B 1.32 B 825 M 909 M 1.03 B 872 M 690 M 542 M 509 M - - -

Shares

46.7 M 48.4 M 48.3 M 48.6 M 47.8 M 47 M 47 M 46.4 M 46.1 M 45.4 M 45 M 42 M - - -

Historical Prices

26.7 27 46.6 36.2 27.7 17.5 15.4 24.9 18.4 15.5 10.5 14 - - -

Net Income

98.1 M 160 M 138 M 91.4 M 62.1 M 1.4 M 48.9 M -5.74 M 4.51 M 10.5 M -2.79 M -10.7 M 11.9 M 18.1 M 7.75 M

Revenue

720 M 732 M 644 M 499 M 438 M 350 M 322 M 295 M 240 M 255 M 252 M 210 M 230 M 204 M 118 M

Cost of Revenue

364 M 358 M 293 M 250 M 238 M 207 M 190 M 188 M 150 M 151 M 174 M 159 M 143 M 114 M -

Gross Profit

356 M 374 M 351 M 249 M 200 M 143 M 132 M 107 M 90.8 M 104 M 77.3 M 51.3 M 87 M 90.3 M 28.1 M

Operating Income

140 M 205 M 197 M 107 M 69.9 M 11 M -39 K -8.62 M -1.27 M 15.4 M -6.9 M -18 M 17.5 M 25.4 M -

Interest Expense

23 K 4.08 M -3.93 M 9.07 M 885 K 374 K 119 K 243 K 826 K 1.02 M 987 K 609 K 958 K 784 K -

EBITDA

172 M 234 M 222 M 131 M 80.1 M 20 M 21.1 M 7.89 M 11.9 M 30.3 M 6.56 M -3.1 M 30.7 M 39 M -22.3 M

Operating Expenses

216 M 168 M 154 M 141 M 130 M 132 M 132 M 116 M 94.3 M 88.5 M 84 M 68.8 M 69.3 M 62.8 M 61.6 M

General and Administrative Expenses

85.9 M 56.7 M 51.5 M 45.1 M 51.4 M 50.4 M 50.3 M 49.9 M 44.5 M 41.8 M 41.5 M 34.8 M 31 M 27.2 M 26.4 M

All numbers in USD currency

Quarterly Income Statement Amphastar Pharmaceuticals

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

46.5 M 46.9 M 47.6 M 47.6 M 48.6 M 48.9 M 48.2 M 48.1 M 48.7 M 48.4 M 48 M 48.1 M 48.9 M 48.9 M 48.1 M 47.7 M 48 M 47.7 M 47.5 M 47.5 M 47.5 M 46.8 M 46.4 M 46.8 M 47.2 M 47.1 M 46.7 M 46.3 M 46.2 M 46.6 M 46.5 M 46.2 M 46.1 M 46 M 46.1 M 46.1 M 45.4 M 45 M 45 M 45.1 M 45.3 M 44.8 M 44.6 M 44.6 K 44.6 K 39.8 K 38.8 K 38.7 M 38.7 M 38.7 M 38.7 M - - - - - - - -

Net Income

17.4 M 31 M 25.3 M - 40.4 M 37.9 M 43.2 M - 49.2 M 26.1 M 26 M - 15.9 M 17.3 M 24.3 M - 29.5 M 7.77 M 5.04 M - 3.92 M -192 K 3.95 M -1.03 M 1.31 M 47.8 M 868 K 1.87 M 2.39 M -2.85 M -7.14 M 1.47 M 99 K 1.97 M 893 K -2.74 M 3.89 M 6.9 M 2.49 M 7.53 M -3.01 M -6.65 M -665 K -2.52 M -5.38 M -1.18 M -1.62 M 1.83 M -160 K 7.81 M 2.38 M - - - - - - - -

Revenue

192 M 174 M 171 M - 191 M 182 M 172 M - 181 M 146 M 140 M - 120 M 123 M 120 M - 112 M 102 M 103 M - 83.4 M 85.8 M 84.7 M 83.4 M 80.1 M 79 M 79.8 M 89.7 M 75.5 M 71 M 58.4 M 60.4 M 57.9 M 65.2 M 56.7 M 63.5 M 64.2 M 68 M 59.4 M 76.9 M 63.9 M 53.9 M 56.9 M 55.9 M 59.7 M 49 M 45.9 M 54.9 M 59.3 M 62.5 M 53 M - - - - - - - -

Cost of Revenue

93.2 M 87.9 M 85.3 M - 89.3 M 87.2 M 81.7 M - 72.2 M 73 M 66.2 M - 61.6 M 60.1 M 64.5 M - 61 M 54.3 M 58.1 M - 46.9 M 52.6 M 47.9 M - 44.9 M 46.7 M 48.9 M - 46.3 M 45 M 41.4 M - 37.4 M 38.4 M 33.8 M - 36.6 M 36.3 M 34.5 M - 46.3 M 40.5 M 43.6 M - 47.9 M 34 M 33.4 M - 39 M 35 M - - - - - - - - -

Gross Profit

98.6 M 86.5 M 85.3 M - 102 M 95.2 M 90.1 M - 108 M 72.7 M 73.8 M - 58.5 M 63.4 M 55.8 M - 51.2 M 47.4 M 44.9 M - 36.5 M 33.2 M 36.8 M 33.4 M 35.3 M 32.4 M 30.9 M 34.7 M 29.3 M 26.1 M 17 M 20.5 M 20.6 M 26.7 M 22.8 M 20 M 27.6 M 31.7 M 24.9 M 33.2 M 17.6 M 13.3 M 13.3 M 12 M 11.8 M 15 M 12.5 M 19.6 M 20.3 M 27.5 M 19.6 M - - - - - - - -

Operating Income

25.3 M 42.2 M 37.3 M - 57 M 55.2 M 48 M - 72.7 M 36.9 M 33.4 M - 23.2 M 24.8 M 21.6 M - 24.8 M 10.6 M 10.3 M - 3.52 M -2.92 M 7.48 M - 2.4 M 973 K -3.17 M - 2.55 M -2.94 M -9.78 M - -2.94 M 2.18 M 1.4 M - 5.8 M 10.3 M 4.08 M - -3.75 M -10.3 M -7.26 M - -7.82 M -1.17 M -1.97 M - 226 K 12 M - - - - - - - - -

Interest Expense

231 K 1.51 M -2.23 M - -5.09 M 298 K 5.92 M - 3.46 M -1.52 M 398 K - 566 K 397 K 355 K - 527 K 86 K 104 K - 175 K 35 K 76 K - 22 K 24 K 30 K - 124 K 100 K 18 K - 264 K 237 K 191 K - 281 K 305 K 384 K - 232 K 210 K 341 K - 504 K 476 K 180 K - 195 K 237 K - - - - - - - - -

EBITDA

39.4 M 56.8 M 44.7 M - 70.4 M 68.4 M 54.8 M - 82.3 M 40 M 36.8 M - 26.6 M 27.8 M 24.4 M - 27.3 M 13.2 M 12.8 M - 5.97 M -894 K 9.53 M - 4.1 M 2.63 M -1.54 M - 13 M 3.57 M -6.72 M - 6.72 M 8.42 M 4.5 M - 14.8 M 16.3 M 7.02 M - 4.77 M -4.63 M -4.49 M - 1.42 M 4.86 M 971 K - 8.41 M 17.4 M - - - - - - - - -

Operating Expenses

73.3 M 44.3 M 48 M - 44.9 M 39.9 M 42.1 M - 35.7 M 35.8 M 40.4 M - 35.3 M 38.5 M 34.2 M - 26.4 M 36.8 M 34.6 M - 33 M 36.1 M 29.3 M - 32.8 M 31.4 M 34.1 M - 26.7 M 29 M 26.7 M - 23.5 M 24.6 M 21.4 M - 21.8 M 21.4 M 20.8 M - 21.3 M 23.6 M 20.5 M - 19.6 M 16.2 M 14.5 M - 20.1 M 15.5 M - - - - - - - - -

General and Administrative Expenses

39.5 M 14 M 16 M - 14.8 M 13.3 M 15.7 M - 12.7 M 12.3 M 13.5 M - 12 M 9.98 M 12.5 M - 10.9 M 14.6 M 15.3 M - 11.7 M 15.9 M 10.7 M - 11 M 12.4 M 16.3 M - 13.4 M 11.7 M 11 M - 11.7 M 12.2 M 11.3 M - 10.8 M 9.46 M 10.9 M - 9.03 M 11.3 M 12.5 M - 9.56 M 8.64 M 6.84 M - 9.54 M 6.51 M - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Amphastar Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.83 1.62 % $ 284 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Esperion Therapeutics Esperion Therapeutics
ESPR
$ 2.86 3.44 % $ 594 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Equillium Equillium
EQ
$ 2.11 2.43 % $ 121 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.31 -1.88 % $ 334 M britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.83 3.79 % $ 138 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Seer Seer
SEER
$ 1.68 -2.9 % $ 107 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Kala Pharmaceuticals Kala Pharmaceuticals
KALA
$ 0.2 -5.13 % $ 759 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 47.57 1.02 % $ 4.28 B schweizSchweiz
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.47 -1.21 % $ 856 M canadaCanada
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Sangamo Therapeutics Sangamo Therapeutics
SGMO
$ 0.34 -2.42 % $ 59.3 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Kazia Therapeutics Limited Kazia Therapeutics Limited
KZIA
$ 6.91 -5.34 % $ 915 M australiaAustralia